Evidence map›Paper›PMID 25071908›Full record

ArticleGut and liver2014

Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.

Yuki Wada, Hideyuki Tamai, Akira Kawashima, Naoki Shingaki, Yoshiyuki Mori, Masanori Kawaguchi, Kosaku Moribata, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue and 4 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yuki WadaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Hideyuki TamaiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Akira KawashimaDepartment of Internal Medicine, Naga Municipal Hospital, Kinokawa, Japan.
Naoki ShingakiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Yoshiyuki MoriSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Masanori KawaguchiDepartment of Gastroenterology, Saiseikai Wakayama Hospital, Wakayama, Japan.
Kosaku MoribataSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Hisanobu DeguchiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Kazuki UedaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Izumi InoueSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Takao MaekitaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Mikitaka IguchiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Jun KatoSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Masao IchinoseSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JPWakayama Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon α-2b plus ribavirin therapy in patients with high viral load genotype 1b hepatitis C.

methodsThe participants consisted of 72 patients with high viral load genotype 1b. The dynamics of viral load within 2 weeks were measured.

resultsSignificant differences between null responders and nonnull responders were noted for interleukin (IL)-28B genotype, amino acid 70 substitution, α-fetoprotein, low-density lipoprotein cholesterol, hyaluronic acid, and viral response. The area under the curve (AUC) for the receiver operating characteristic curve of the hepatitis C virus (HCV) RNA level decline at 2 weeks (AUC=0.993) was the highest among the factors predicting the null response. When the cutoff value for the HCV RNA level decline at 2 weeks was set at 0.80 log, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in predicting a null response were 82%, 96%, 82%, 96%, and 94%, respectively. In comparison, values for the non-TT and mutant type of amino acid 70 substitution were similar to those for HCV RNA level decline at 2 weeks.

conclusionsVirological response at 2 weeks or the combination of IL-28B and amino acid 70 substitution are accurate predictors of a null response.

Indexed as

Administration, OralAdultAgedAntiviral AgentsArea Under CurveDrug Therapy, CombinationFemaleGenotypeHepatitis C, ChronicHumansInjections, SubcutaneousInterferon-alphaInterferon alpha-2MaleMedication AdherencePolyethylene GlycolsAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, ViralAmino acid substitutionHepatitis C virusPeginterferon alfa-2bRibavirinSingle nucleotide polymorphisms

Identifiers

PMID25071908
PMCPMC4113039
OpenAlexW2076963895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.